ClinicalTrials.gg
TerminatedNCT05416086Updated Apr 13, 2026

iCLAS™ Cryoablation System Post-Market Clinical Follow-up (PMCF) Study

An interventional study of cryoablation procedure using the iCLAS Cryoablation System in Atrial Fibrillation, Atrial Flutter and Paroxysmal Atrial Fibrillation, sponsored by Adagio Medical. Terminated at 4 sites in 3 countries. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-04-13.

Sponsored by Adagio Medical · Not applicable, Interventional, and Treatment

How we know

Why this study was terminated
Adagio Medical no longer manufactures the iCLAS Cryoablation System

From the registry’s dates

  • Registered 9 months after the study started (first participant enrolled Sep 2021, registered Jun 2022).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
91
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 255 studies in Atrial Fibrillation with a site in Netherlands — 33 open to participants now, 49 under way, 2 of them phase 3. Atrial Fibrillation · Netherlands.

Enrollment
149th of 192
91 · median 250
Started
2021
with 10 others
No phase
106 of 255
19 open now
Registered
199th of 255
by date

Among the 255 studies in Atrial Fibrillation with a site in Netherlands, this one is the 149th largest by enrollment of the 192 interventional ones that give a count, is one of 11 that started in 2021, is one of 106 with no phase, and was the 199th registered.

Atrial Fibrillation

4,018 studies on the registry are indexed under Atrial Fibrillation; 965 are open to participants now.

Browse Atrial Fibrillation studies →

Open to participants now

33 of the 255 studies in Atrial Fibrillation with a site in Netherlands are open now. Recruiting first, the newest first:

28 more — sign in →

All 33 open studies →

A study can be open while its sites in Netherlands have not opened yet or have stopped. Only those recruiting at a site in Netherlands →

Who these studies take

Of the 613 Atrial Fibrillation studies recruiting now, 410 (67%) set no upper age limit and 44 (7%) stop at 75 or younger; 21 take children under 18; 43 take healthy volunteers.

This study: 18 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 255 studies in Atrial Fibrillation with a site in Netherlands, or all of them as a file.
02

Study summary

A prospective, single-arm, multi-center study designed to collect real world safety and performance data of the Adagio Medical iCLAS Cryoablation System in the treatment of drug refractory, recurrent, symptomatic, Paroxysmal Atrial Fibrillation (PAF), Persistent Atrial Fibrillation (PsAF), and Atrial Flutter (AFL).

Read the detailed description

This Post-Market Clinical Follow-up (PMCF) study continues collecting additional information about the Adagio Medical iCLAS™ Cryoablation System in real world clinical settings.

03

Conditions studied

  • Atrial Fibrillation
  • Atrial Flutter
  • Paroxysmal Atrial Fibrillation
  • Persistent Atrial Fibrillation
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subject is ≥ 18 years of age
  • Planned ablation procedure according to the indication for use of the commercially available Adagio iCLAS™ Cryoablation System
  • Subject willing to comply with study requirements and give .

Exclusion criteria

Exclusion Criteria:

  • In the opinion of the Investigator, any known to an atrial ablation procedure with the Adagio iCLAS™ Cryoablation System as indicated in the device Instructions For Use (IFU).
  • Subject is enrolled in a study that has not been approved for concurrent enrollment by the sponsor.
  • Any other condition that, in the judgment of the investigator, makes the patient a poor candidate for this procedure, the study or compliance with the protocol (includes vulnerable patient population, mental illness, addictive disease, terminal illness with a of less than one year, extensive travel away from the research center)
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
91 participants (actual)

Study arms

  • Other
    iCLAS Cryoablation arm

    all subjects will receive a cryoablation procedure with the iCLAS System and be followed up for 12-month

    Device: cryoablation procedure using the iCLAS Cryoablation System

Interventions

  • Devicecryoablation procedure using the iCLAS Cryoablation System

    all subjects will receive a cryoablation procedure using the iCLAS Cryoablation System (catheter, stylets, and console) and warming balloon

06

What researchers measure

Primary outcomes

  1. Primary outcome - freedom from AF

    Freedom from Atrial Fibrillation (AF) recurrence during the 12-months follow-up period.

    Time frame: 12 months

  2. Primary outcome - freedom from AF/AT/AFL

    Freedom from Atrial Arrhythmia at 12-months

    Time frame: 12 months

  3. Primary outcome - freedom from Device/Procedure Related Adverse Events

    Freedom from Device / Procedure Related Adverse Events during and after the ablation procedure through12-month follow up

    Time frame: during procedure and up to 12-month follow up

07

Study locations

4 sites
  • Onze-Lieve-Vrouw Hospital Aalst (OLV)
    Aalst, 9300, Belgium
  • Universitatsklinikum Erlangen
    Erlangen, 91054, Germany
  • St. Antonius Ziekenhuis
    Nieuwegein, 3435, Netherlands
  • Erasmus MC
    Rotterdam, Netherlands
08

References and documents

Publications

  • Abeln BGS, Addeo L, De Potter T, Boersma LVA. Durability of Ultra-Low Temperature Cryoablation Lesions in Atrial Fibrillation: Insights From Repeat Ablation Procedures. J Cardiovasc Electrophysiol. 2025 Jun;36(6):1264-1271. doi: 10.1111/jce.16665. Epub 2025 Mar 27. PubMed 40150915 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Sep 2021 to primary completion in Jan 2025, 40 months.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 7, 2022
First posted
Jun 13, 2022
StartActual
Sep 3, 2021
Primary completionActual
Jan 28, 2025
CompletionActual
Jan 28, 2025
Last update
Apr 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 13, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05416086
Lead sponsor
Adagio Medical
Responsible party
Sponsor
First posted
Jun 13, 2022
Start date
Sep 3, 2021
Primary completion
Jan 28, 2025
Completion
Jan 28, 2025
Last update
Apr 13, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion